Maternal serum angiopoietin-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy

被引:9
作者
Akolekar, Ranjit [1 ]
Casagrandi, Davide [1 ]
Skyfta, Evdoxia [1 ]
Ahmed, Abubaker Abdalla [1 ]
Nicolaides, Kypros H. [1 ]
机构
[1] Kings Coll Hosp, Harris Birthright Res Ctr Fetal Med, London, England
关键词
angiopoietin-2; first-trimester screening; preeclampsia; uterine artery Doppler; NUCHAL-TRANSLUCENCY THICKNESS; ENDOTHELIAL GROWTH-FACTOR; UTERINE ARTERY DOPPLER; PLASMA PROTEIN-A; ANGIOGENIC FACTORS; PREECLAMPSIA; PREDICTION; RISK; TIE2; AGE;
D O I
10.1002/pd.2307
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objective In women with preeclampsia (PE), the serum concentration of the growth factor angiopoietin-2 (Ang-2) is significantly lower than in unaffected controls. The objective of this study is to determine if the decrease in serum Ang-2 is evident from the first trimester of pregnancy before the clinical onset of PE. Methods Serum Ang-2 and uterine artery pulsatility index (PI.) were measured at I I to 13 weeks in 126 pregnancies that subsequently developed PE, 88 cases that developed gestational hypertension (GH) and 214 unaffected controls. Results Maternal serum Ang-2 in the PE group [0.96 multiple of the median (MoM)] and in GH (1.12 MoM) was not significantly different from the unaffected group (1.07 MoM). Uterine artery PI was significantly higher in the PE group (1.32 MoM) but not in GH (1.11 MoM) compared to the unaffected group (1.05 MoM). Conclusion In pregnancies that develop PE there is Doppler evidence of impaired placentation from the first trimester of pregnancy. However, the impaired placentation is not reflected in altered maternal serum levels of Ang-2. Copyright (c) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:847 / 851
页数:5
相关论文
共 24 条
[1]   Maternal serum placental growth factor at 11+0 to 13+6 weeks of gestation in the prediction of pre-eclampsia [J].
Akolekar, R. ;
Zaragoza, E. ;
Poon, L. C. Y. ;
Pepes, S. ;
Nicolaides, K. H. .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2008, 32 (06) :732-739
[2]   Mechanisms of angiogenesis and arteriogenesis [J].
Carmeliet, P .
NATURE MEDICINE, 2000, 6 (04) :389-395
[3]   Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation [J].
Charnock-Jones, DS ;
Kaufmann, P ;
Mayhew, TM .
PLACENTA, 2004, 25 (2-3) :103-113
[4]   THE CLASSIFICATION AND DEFINITION OF THE HYPERTENSIVE DISORDERS OF PREGNANCY [J].
DAVEY, DA ;
MACGILLIVRAY, I .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1988, 158 (04) :892-898
[5]  
Ferrara N, 2000, RECENT PROG HORM RES, V55, P15
[6]   Human placental vascular development: Vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2 [J].
Geva, E ;
Ginzinger, DG ;
Zaloudek, CJ ;
Moore, DH ;
Byrne, A ;
Jaffe, RB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (09) :4213-4224
[7]   Increase of serum angiopoietin-2 during pregnancy is suppressed in women with preeclampsia [J].
Hirokoshi, K ;
Maeshima, Y ;
Kobayashi, K ;
Matsuura, E ;
Sugiyama, H ;
Yamasaki, Y ;
Masuyama, H ;
Hiramatsu, Y ;
Makino, H .
AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (09) :1181-1188
[8]   Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A [J].
Kagan, K. O. ;
Wright, D. ;
Baker, A. ;
Sahota, D. ;
Nicolaides, K. H. .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2008, 31 (06) :618-624
[9]   INADEQUATE MATERNAL VASCULAR-RESPONSE TO PLACENTATION IN PREGNANCIES COMPLICATED BY PREECLAMPSIA AND BY SMALL-FOR-GESTATIONAL-AGE INFANTS [J].
KHONG, TY ;
DEWOLF, F ;
ROBERTSON, WB ;
BROSENS, I .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1986, 93 (10) :1049-1059
[10]   Circulating angiogenic factors and the risk of preeclampsia [J].
Levine, RJ ;
Maynard, SE ;
Qian, C ;
Lim, KH ;
England, LJ ;
Yu, KF ;
Schisterman, EF ;
Thadhani, R ;
Sachs, BP ;
Epstein, FH ;
Sibai, BM ;
Sukhatme, VP ;
Karumanchi, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (07) :672-683